

# Eri T Kato

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/710389/publications.pdf>

Version: 2024-02-01

24  
papers

8,934  
citations

623188

14  
h-index

713013

21  
g-index

24  
all docs

24  
docs citations

24  
times ranked

8812  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2019, 380, 347-357.	13.9	4,159
2	SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. <i>Lancet</i> , The, 2019, 393, 31-39.	6.3	1,958
3	Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1217-1227.	13.9	780
4	Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 139, 2022-2031.	1.6	523
5	Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2019, 7, 606-617.	5.5	482
6	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 139, 2528-2536.	1.6	415
7	Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	215
8	The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. <i>American Heart Journal</i> , 2018, 200, 83-89.	1.2	117
9	<scp>DECLARE-TIMI</scp> 58: Participants' baseline characteristics. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1102-1110.	2.2	96
10	Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	43
11	Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation. <i>Ageing Research Reviews</i> , 2019, 49, 115-124.	5.0	34
12	Important Regulatory Role of Activated Platelet-Derived Procoagulant Activity in the Propagation of Thrombi Formed Under Arterial Blood Flow Conditions. <i>Circulation Journal</i> , 2009, 73, 540-548.	0.7	27
13	The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 468-474.	0.4	18
14	Intravascular ultrasound-guided percutaneous coronary interventions with minimum contrast volume for prevention of the radiocontrast-induced nephropathy: report of two cases. <i>Cardiovascular Intervention and Therapeutics</i> , 2011, 26, 83-88.	1.2	16
15	The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. <i>Diabetologia</i> , 2021, 64, 1226-1234.	2.9	15
16	Sodium-glucose Co-transporters-2 Inhibitors and Heart Failure: State of the Art Review and Future Potentials. <i>International Journal of Heart Failure</i> , 2020, 2, 12.	0.9	15
17	Response by Kato et al to Letter Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus". <i>Circulation</i> , 2019, 140, e740-e741.	1.6	6
18	Direct comparison of optical coherence tomography and high-definition 60-MHz intravascular ultrasound imaging of intra-procedural stent thrombosis in a patient with acute coronary syndrome. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 365-367.	0.3	5

#	ARTICLE	IF	CITATIONS
19	Antihyperglycemic therapies and cardiovascular outcomes in patients with type 2 diabetes mellitus: State of the art and future directions. Trends in Cardiovascular Medicine, 2021, 31, 101-108.	2.3	5
20	A method and preliminary results of <i>in silico</i> computer simulation for the formation of mix thrombi with platelet and fibrin. Journal of Biorheology, 2017, 31, 30-34.	0.2	4
21	Ischemic and Bleeding Events After First Major Bleeding Event in Patients Undergoing Coronary Stent Implantation. American Journal of Cardiology, 2022, 162, 13-23.	0.7	1
22	Potential difficulty for accurate categorization of drug-eluting stent thrombosis without coronary angiography: unignorable involvement of the cases with new onset acute myocardial infarction occurred in target vessels. Cardiovascular Intervention and Therapeutics, 2011, 26, 109-116.	1.2	0
23	A simple method preventing tangling of the guidewires during percutaneous coronary intervention for bifurcation lesions. Cardiovascular Intervention and Therapeutics, 2011, 26, 117-123.	1.2	0
24	Modifiers of the Risk of Diabetes for Long-Term Outcomes After Coronary Revascularization. JACC Asia, 2022, , .	0.5	0